Publication

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

Authors not recorded

J Pathol2015PMID 25424858PMC4643177stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerMalignant Breast Neoplasmcivic_curation1.00
drugSpliceostatin Acivic_curation1.00
geneSF3B1civic_curation1.00
variantSF3B1 K666Ncivic_curation1.00
variantSF3B1 K700Ecivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SF3B1 K666N1
Spliceostatin A	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1418 Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 m… (full text at CIViC) PMID 25424858 · Maguire et al., 2015 · Open in CIViC	civic
SF3B1 K700E1
Spliceostatin A	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1417 Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 m… (full text at CIViC) PMID 25424858 · Maguire et al., 2015 · Open in CIViC	civic